The role of mutations in epigenetic regulators in myeloid malignancies
- PMID: 22898539
- DOI: 10.1038/nrc3343
The role of mutations in epigenetic regulators in myeloid malignancies
Abstract
Recent genomic studies have identified novel recurrent somatic mutations in patients with myeloid malignancies, including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). In some cases these mutations occur in genes with known roles in regulating chromatin and/or methylation states in haematopoietic progenitors, and in other cases genetic and functional studies have elucidated a role for specific mutations in altering epigenetic patterning in myeloid malignancies. In this Review we discuss recent genetic and functional data implicating mutations in epigenetic modifiers, including tet methylcytosine dioxygenase 2 (TET2), isocitrate dehydrogenase 1 (IDH1), IDH2, additional sex combs-like 1 (ASXL1), enhancer of zeste homologue 2 (EZH2) and DNA methyltransferase 3A (DNMT3A), in the pathogenesis of MPN, MDS and AML, and discuss how this knowledge is leading to novel clinical, biological and therapeutic insights.
Similar articles
-
The Impact of Epigenetic Modifications in Myeloid Malignancies.Int J Mol Sci. 2021 May 9;22(9):5013. doi: 10.3390/ijms22095013. Int J Mol Sci. 2021. PMID: 34065087 Free PMC article. Review.
-
[Research on molecular markers for epigenetic changes in myeloid malignancies].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013 Dec;30(6):687-92. doi: 10.3760/cma.j.issn.1003-9406.2013.06.012. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013. PMID: 24327148 Review. Chinese.
-
Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.J Exp Med. 2013 Nov 18;210(12):2627-39. doi: 10.1084/jem.20131144. Epub 2013 Nov 11. J Exp Med. 2013. PMID: 24218139 Free PMC article.
-
A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.Int J Lab Hematol. 2024 Aug;46(4):687-694. doi: 10.1111/ijlh.14280. Epub 2024 Apr 26. Int J Lab Hematol. 2024. PMID: 38665121
-
Mutations in epigenetic regulators in myelodysplastic syndromes.Int J Hematol. 2012 Jan;95(1):8-16. doi: 10.1007/s12185-011-0996-3. Epub 2012 Jan 11. Int J Hematol. 2012. PMID: 22234528 Review.
Cited by
-
CD133 marks a stem cell population that drives human primary myelofibrosis.Haematologica. 2015 Jun;100(6):768-79. doi: 10.3324/haematol.2014.118463. Epub 2015 Feb 27. Haematologica. 2015. PMID: 25724578 Free PMC article.
-
Targeting cell cycle regulators in hematologic malignancies.Front Cell Dev Biol. 2015 Apr 9;3:16. doi: 10.3389/fcell.2015.00016. eCollection 2015. Front Cell Dev Biol. 2015. PMID: 25914884 Free PMC article. Review.
-
Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy.Cancers (Basel). 2021 Apr 6;13(7):1746. doi: 10.3390/cancers13071746. Cancers (Basel). 2021. PMID: 33917538 Free PMC article. Review.
-
Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Semin Hematol. 2015 Jul;52(3):172-83. doi: 10.1053/j.seminhematol.2015.04.003. Epub 2015 Apr 8. Semin Hematol. 2015. PMID: 26111464 Free PMC article. Review.
-
High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer.Blood Adv. 2024 Feb 27;8(4):846-856. doi: 10.1182/bloodadvances.2023011262. Blood Adv. 2024. PMID: 38147626 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous